Abstract
frequently followed by loss of heterozygosity, which further increases the drug resistance of 48 the resulting homozygous strains. Indeed, loss of heterozygosity has been observed in many 49 fluconazole-resistant clinical isolates containing mutations in ERG11, MRR1, or TAC1 (3-6, 50 14, 18, 29). Similarly, loss of heterozygosity has also been found in a fluconazole-resistant 51 strain with a gain-of-function mutation in Upc2, the transcriptional regulator of ERG11 and 52 other ergosterol biosynthesis genes (9). 53
The diploid genome of C. albicans exhibits a high degree of heterozygosity (12). In a given 54 strain, the two alleles of a gene usually are not identical but differ from one another to various 55 degrees. It has been recently reported that two types of MDR1 alleles exist in C. albicans, 56 which can be distinguished by specific polymorphic nucleotides in the promoter region (2). 57
One of these promoter alleles was found to confer higher MDR1 expression than the other 58 allele. Many clinical isolates contained two alleles of the higher activity type, whereas strains 59 containing only the less active allele were rare, and it was suggested that the higher activity 60 alleles of the MDR1 promoter could promote the development of drug resistance (2). These 61 observations indicated that in strains containing both types of MDR1 alleles, loss of 62 heterozygosity would be an additional mechanism of increased drug resistance. 63 on November 12, 2017 by guest http://aac.asm.org/ Downloaded from 6 As explained above, the low basal expression levels of MDR1 do not contribute to the wild-116 type tolerance of subinhibitory fluconazole concentrations in drug-susceptible strains. Bruzual 117 and Kumamoto used a fluconazole-resistant strain containing a gain-of-function mutation in 118
Mrr1 to compare the activities of four A-type and four G-type MDR1 promoters in an 119 isogenic background (2). They found that the A-type promoters were on average fivefold 120 more active than the G-type promoters. To compare the constitutive activity of the two MDR1 121 promoter alleles of strain SC5314 in the presence of a hyperactive Mrr1, we introduced the 122 reporter fusions into a derivative of this strain in which the endogenous MRR1 alleles had 123 been replaced by the MRR1 P683S allele from a fluconazole-resistant clinical isolate. Fig. 1B  124 shows that both MDR1 promoters were constitutively activated at comparable levels in the 125 presence of a hyperactive Mrr1. 126
The bZip transcription factor Cap1 is also involved in the regulation of MDR1 expression (1, 127 21, 25) . No gain-of-function mutations in Cap1 have been found so far in fluconazole-128 resistant clinical C. albicans isolates, but a C-terminally truncated Cap1 is hyperactive and 129 constitutively activates the MDR1 promoter, albeit less efficiently than does hyperactive Mrr1 130 (1, 25) . To assess whether this hyperactive Cap1 might differentially activate the two types of 131 MDR1 promoter alleles, the reporter fusions were also introduced into a derivative of strain 132 SC5314 in which the endogenous CAP1 alleles had been replaced by the CAP1 ΔC333 allele. As 133 can be seen in Fig. 1B , both MDR1 promoter alleles were activated to similar levels by the 134 hyperactive Cap1. These results demonstrate that the two MDR1 alleles of strain SC5314 are 135 equally well activated by two different hyperactive transcription factors controlling MDR1 136 expression and would therefore be expected to contribute equally to the increased drug 137 resistance of such strains. 138
The findings that A-type MDR1 promoters exhibited higher activity than G-type promoters 139
and that homozygosity for A-type promoters was common in clinical C. albicans isolates, 140 whereas homozygosity for G-type promoters was rarely observed, has led to the hypothesis 141 the MDR1 promoter sequences demonstrated that both alleles of these isolates were of the G 156 type, although one of the two alleles had a T at position -343 instead of the A that usually 157 occurs at this position in G-type promoters ( Table 1 ). This result demonstrated that the A at 158 position -343 is not invariably linked with the other 4 diagnostic nucleotides in G-type alleles. 159
In addition, and contrary to expectations, in these two cases MDR1 overexpression and 160 fluconazole resistance developed in strains that contained only G-type alleles. 161
To investigate if loss of heterozygosity at the MDR1 locus occurred in other MDR1 162 overexpressing, fluconazole-resistant clinical C. albicans isolates, we determined the MDR1 163 promoter sequences in seven additional isolate pairs in which the resistant isolate had 164 acquired a gain-of-function mutation in Mrr1 and overexpressed MDR1 (5). For this purpose, 165 the MDR1 promoters of these isolates were amplified by PCR and the PCR products were 166 directly sequenced (Table 1) host strain containing a hyperactive Mrr1 and found that all A-type promoters produced 213 higher amounts of GFP mRNA than did the G-type promoters (2). One of the A-type 214 promoters was from strain CAI4, a derivative of strain SC5314, but the G-type allele from 215 this strain was not included for comparison in that study. Our results indicate that no 216 differences between the activities of these two promoter alleles would have been observed. 217
The different activities of the various MDR1 promoters that were reported in that study must 218 on November 12, 2017 by guest http://aac.asm.org/ Downloaded from therefore be due to other sequence differences than those found in the alleles of strain SC5314 219 (Fig. S1) . 220
Our results imply that in strain SC5314 loss of heterozygosity for the MDR1 promoter would 221 not increase MDR1 expression and therefore not contribute to the development of fluconazole 222 resistance. In this respect, it is interesting to note that fluconazole-resistant derivatives of 223 strain SC5314, which were selected in vitro during growth in the presence of fluconazole, 224 retained both polymorphic MDR1 alleles, demonstrating that loss of heterozygosity at the 225 MDR1 locus did not play a role in fluconazole resistance development in any of these strains 226 contained two different MDR1 promoter alleles, which were retained in the corresponding 239 resistant isolates, i.e., in none of these cases did we observe loss of heterozygosity ( Table 1) . deviations from four to five independent cultures). The following strains were used (see 398   Table S1 ): SCMPG2S2A and -B (wild type, P MDR1-1 ), SCMPG2A and -B (wild type, P MDR1-2 ), 399 
